INTRODUCTION
Androgen leads follicular atresia in murine experimental models (Fabregues et al., 2009 ). However, in primates, androgens had positive effects about follicular development and some synergistic effects with follicle stimulating hormone (FSH) . Androgen supplementation such as testosterone or dihydrotestosterone recruited more growing follicles, and increased granulosa and theca cell proliferation . Furthermore, androgen makes follicular FSH receptor expression in granulosa cells (Weil et al., 1999) .
These androgen actions showed some helpful outcomes during in vitro fertilization (IVF) treatment especially for poor ovarian responders (Fabregues et al., 2009; Barad & Gleicher, 2006) .
Poor ovarian response to ovarian stimulation usually indicates a reduced follicular response during assisted reproduction. According to a consensus developed by The European Society for Human Reproduction and Embryology, less than 3 oocytes could be retrieved with a conventional stimulation protocol in poor responders by definition (Ferraretti et al., 2011) . So a variety of stimulation protocols have been used, however none of them have been so effective for poor ovarian response. Androgen supplementation protocol is one of them (Gonzalez-Comadran et al., 2012) , which have been investigated upon data from experimental animals described above and speculation from women with poly-cystic ovarian syndrome (Massin et al., 2006) .
In human data, there was controversy about androgen priming during assisted reproduction. The oral dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve showed increased ovarian responsiveness and demonstrated significant improved IVF outcomes (Barad & Gleicher, 2006; Casson et al., 2000) . Transdermal testosterone pretreatment also showed increased ovarian sensitivity to gonadotropin (Fabregues et al., 2009 ).
However, Massin et al. could not demonstrate any beneficial effect on ovarian response to gonadotropin depending on testosterone application. They proposed several reasons about the absence of any beneficial effects of testosterone application, and timing and duration of androgen supplementation were thought to be critical in adequate follicle stimulation and total amount of androgen supplementation was also considered to be an important factor (Massin et al., 2006) .
Therefore we conducted a pilot study to investigate the effect of transdermal testosterone gel (TTG) among subgroups classified by use duration in patients who had experienced a poor ovarian response to prior IVF cycles. We observed and compared ovarian morphologies of each groups including antral follicle count, follicular diameter and intra-ovarian blood flow after TTG treatment.
MATERIAL AND METHODS

Patients
The study population consisted of total 120 women, and they had been showed poor ovarian responses during prior failed IVF cycles. In detail, women were enrolled who failed to produce over 3 follicles with a mean diameter of ≥ 16 mm, and then less than 3 follicle were retrieved even a high total dose of recombinant human follicle stimulating hormone(rhFSH, > 2,500 IU). All the patients were in good health within normal limits of thyroid, kidney and hepatic laboratory results, and they had regular menstruation period with duration 21-35 days. None of them had ever taken any infertility medication over past 3 months. Our pilot study was performed at a university-based infertility clinic at the Asan Medical Center, Seoul, South Korea.
The study population consisted of 120 poor responders who had undergone 120 IVF/ICSI cycles between Jan 2006 and Jan 2010. Patients were randomly allocated into three TTG treatment groups (TTG use for 2 weeks, 3 weeks or 4 weeks) (n=30 in each groups) and one control group (n=30) by the use of sealed envelopes and a computer-generated list. The sequence of allocation to the four groups was provided to the investigating physicians and randomization was performed as planned according to the randomization list order.
Ovarian stimulation protocol
Before starting COS cycle, all of the patients had taken estrogen and progesterone pretreatment for 25 days using 
TTG pretreatment
For three TTG pretreatment subgroups, 12.5 mg TTG (Testo gel 1%; Laboratories Besins International, Paris, France) with a 1.25 mg/d nominal delivery rate of testosterone was applied once daily in the morning, which was administered by the patient onto clean dry healthy skin over both upper arms. This testosterone gel formulation is a hydroalcoholic gel containing 1% testosterone, and approximately 9-14% of the steroid in the gel is available in the body (Wang et al., 2004) . The dose of TTG, 12.5 mg/d was determined on the basis of experimental data in primates Vendola et al., 1999) . Once gel applied, patients were instructed to avoid washing the application sites, for 5 hours, but washed their hands thoroughly with soap and water. The duration of TTG pretreatment was varied among the study subgroups, which were 2, 3 and 4 weeks respectively in prece-ding period of study stimulation cycle. Ovarian stimulation was started next day of last testosterone gel application.
Outcome measures
The primary end point was the total number of mature retrieved oocytes. The secondary endpoints were the number of growing follicles, numbers of fertilized oocytes and good-quality embryos. We also evaluated and analyzed total dose and days of rhFSH administered, implantation rate, clinical pregnancy rate per cycle, and live birth rate 
Statistical analysis
Results were presented as the mean ± standard deviation (SD) with 95% confidence interval. All statistical analysis was performed using SPSS statistical package for Windows, version 11.0 (SPSS Inc, Chicago, IL). Analysis of variance (ANOVA) was performed to compare the mean values among four groups. Chi-square test, and Fisher's exact test were performed for the comparisons of fraction, where applicable. P<0.05 was considered to be obtained statistical significance. The 25% of circulating testosterone comes from ovary in regularly cycling women, and these levels appeared to decrease with age (Barbieri et al., 2005) . Similarly, women with lower ovarian reserve were predicted to have low testosterone levels like aging women, even though it's subclinical. According to testosterone threshold analysis during IVF cycles, higher baseline testosterone level appeared to be associated with successful pregnancy (Frattarelli & Peterson, 2004 (Barbieri et al., 2005) . In this perspective, basal hormonal secretion should be more carefully assessed for poor ovarian responders and they could be affected by testosterone level more than who are not a poor responders during gonadotropin stimulation.
RESULTS
As presented in
Poor ovarian response was reported as 9-25% of assisted reproduction (de los Santos et al., 2013) . Several strategies have not fulfilled to increase reproductive outcomes for these poor responders, and commonly used approach is to make a high androgen intra-ovarian environment. So, dehydroepiandrosterone (DHEA), transdermal testosterone, aromatase inhibitor or recombinant luteinizing hormone (LH) was commonly administered in clinical practice (de los Santos et al., 2013; Fanchin et al., 2011) . The roles of androgens in ovarian folliculogenesis have been proposed, and basically androgens are essential substrates for ovarian steroidogenesis according to 2-cell two-gonadotropin theory (Ryan et al., 1968) . Mediated by androgen receptor, testosterone and dihydrotestosterone (DHT) have made preantral and small antral follicular growth significantly in primates'
ovaries. Granulosa and theca cell proliferation were significantly increased also in these follicles . Insulin-like growth factor I (IGF-I) and IGF-I receptor mRNA were markedly increased in primordial follicle oocytes in the testosterone or DHTtreated monkeys . They suggested androgens stimulate early, gonadotropin independent stages of follicular growth and enhance responsiveness to gonadotropin Weil et al., 1998) .
In the study about human granulosa cells and follicular fluids of small antral follicles, significant correlative mRNA expression was observed between androgen receptor and FSH receptor. Furthermore, follicular fluid testosterone levels were highly significantly correlated with FSH receptor mRNA expression (Nielsen et al., 2011 of absorption approximately. They restricted the duration of application to prevent any side effects (Massin et al., 2006) . The timing and duration of testosterone supplementation, and moreover the total amount of supplementation were presented as critical factors for absence of testosterone priming effect.
In this point, our trial has some strengths and favorable results. Most of all, the study was designed to reveal testosterone effect according to the duration of application.
The positive effects to ovarian stimulation were observed and moreover IVF outcomes were improved after 3 to 4 weeks of testosterone gel application. CPR were significantly increased up to 36.7% especially after 4 weeks TTG treatment. These results could be highlighted because the study population was poor responder. However, data on the dose-response effects of androgens are still limited. In primates study, the threshold effect of androgens on follicular function has been postulated. When high dose of androgens were used for 5 days before and continuing through out FSH and LH treatment, antagonistic actions to gonadotropin stimulation were observed (Zeleznik et al., 2004) . Furthermore intra-ovarian bioavailability of androgens administered systemically at nonvilrilzing dose needs further investigation (Fanchin et al., 2011) . The proper duration of androgen pretreatment should be taken into consideration also. Considering androgens' effect to early stage follicles, pretreatment duration could be taken for several weeks before ovarian stimulation , but TTG should be applied for the shortest duration with positive effect.
Ovarian morphology in circumstances of androgen excess is well known from patients of polycystic ovarian syndrome (PCOS). It is characterized by excessive AFCs, which have been positively correlated with circulating androgen concentrations Pigny et al., 2003) . In case of congenital adrenal hyperplasia or some virilizing tumors, which exposed women to androgen for long duration, comparable ovarian morphologies in PCOS were observed (Fanchin et al., 2011) . After high doses testosterone taken by noncastrated female to male transsexuals, multifollicular ovarian pattern like PCOS was observed by some investigators (Futterweit & Deligdisch, 1986; Pache et al., 1991) . In our study, after 3 weeks of TTG treatment, AFCs were significantly increased and MFD was significantly decreased. Because androgen promotes early stages of follicular growth, MFD had been thought to be decreased. The improvement of intra-ovarian blood flow was demonstrated also, and further investigations are required.
In conclusion, TTG pretreatment for 3 to 4 weeks before ovarian stimulation increases AFC and ovarian stromal blood flow and therefore, potentially can improve the ovarian response to COS and IVF outcome in poor responders undergoing IVF/ICSI.
